Guidance for the notification of serious breaches of GCP or the trial protocol

Table of Contents

Page Number(s):

A. Legal requirement

B. Purpose of the requirement

C Purpose of this guidance

D. Arrangements for notification

E. Identifying serious breaches

F. Potential actions by the MHRA

Appendix I: Notification Examples

Appendix II: Notification Form

Clinical Research News

Kommande kliniska prövningar

NCT04840316

Ännu inte rekryterat

INcidence of PostOperative Delirium Incidence in Surgical Patients: an Observational Cohort Study in New Zealand

Villkor: Delirum; Complication,Postoperative
NCT04840329

Rekrytering

Endocation: Pilot Randomized Cluster Controlled Trial of an Endometriosis Education Program

Villkor: Endometriosis
NCT04840342

Ännu inte rekryterat

MR Antagonist and LSD1

Villkor: Hypertension; Mineralocorticoid Excess
NCT04840368

Ännu inte rekryterat

Cardiovascular Risk and Functional Responses From Dancing at Home in the Elderly With and Without Type 2 Diabetes

Villkor: Aging; Type2 Diabetes
NCT04840394

Ännu inte rekryterat

Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Villkor: Tumor, Solid
NCT04840420

Ännu inte rekryterat

An Effectiveness-implementation Hybrid Study of Social Prescribing in a Singapore Community Hospital Setting

Villkor: Social Isolation
NCT04840485

Ännu inte rekryterat

Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis

Villkor: Ankylosing Spondylitis
NCT04840589

Ännu inte rekryterat

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

Villkor: Metastatic Malignant Solid Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Platinum-Resistant Ovarian Carcinoma; Refractory Ovarian Carcinoma
NCT04840602

Ännu inte rekryterat

Testing the Addition of a New Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Villkor: Lymphoplasmacytic Lymphoma; Waldenstrom Macroglobulinemia
NCT04840615

Rekrytering

Phase I Study of Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma

Villkor: Mesothelioma

Recent CRA jobs